Clinical trial results of new therapies for HBV: Implications for treatment guidelines

Seminars in Liver Disease

Volumn 25, Issue SUPPL. 1, 2005, Pages 29-39

  Gish, Robert G ^a  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

Author keywords

Entecavir; Hepatitis B; Nucleoside analogue; Pegylated interferon

Indexed keywords

16ALPHA BROMOEPIANDROSTERONE; 2 AMINO 9 (1 PHOSPHONOMETHOXYCYCLOPROPYLMETHYL)PURINE BIS(PIVALOYLOXYMETHYL) ESTER; ADEFOVIR DIPIVOXIL; ALAMIFOVIR; ALPHA2B INTERFERON; ALS 920; AMDOXOVIR; ANTIVIRUS AGENT; BAM 205; CLEVUDINE; EHT 899; EMTRICITABINE; ENTECAVIR; LAMIVUDINE; MIV 210; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PRADEFOVIR; RECOMBINANT ALPHA2B INTERFERON; TELBIVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; THYMOSIN ALPHA1; UNCLASSIFIED DRUG; UT 231; VALTORCITABINE;

ABDOMINAL PAIN; ALOPECIA; ANTIVIRAL ACTIVITY; CLINICAL TRIAL; COUGHING; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; ERYTHEMA; FATIGUE; FLU LIKE SYNDROME; HEADACHE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RHINOPHARYNGITIS; RISK BENEFIT ANALYSIS; SIDE EFFECT; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VIRUS RESISTANCE;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; HEPATITIS B; HUMANS; PRACTICE GUIDELINES;

EID: 24344436307     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-915648     Document Type: Review

References (60)

1. Hepatitis B Foundation. What is hepatitis B? Statistics 2005:18
2. Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. Lancet 2003;362:2089-2094
3. Moyer LA, Mast EE. Hepatitis B: virology, epidemiology, disease, and prevention, and an overview of viral hepatitis. Am J Prev Med 1994;10(suppl):45-55
4. World Health Organization Department of Communicable Disease Surveillance and Response. Hepatitis B-an introduction. Available at: www.who.int/emc- documents/hepatitis/docs/whocdscsrlyo20022/introduction/introduction.html. Last update: January, 2005. Accessed May 5, 2005
5. Cihlar T, Lin DC, Pritchard JB, Fuller MD, Mendel DB, Sweet DH. The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1. Mol Pharmacol 1999;56:570-580
6. Lok AS. New treatment of chronic hepatitis B. Semin Liver Dis 2004;24(suppl 1):77-82
7. Marcellin P. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348:808-816
8. Santantonio T, Mazzola M, Iacovazzi T, Miglietta A, Guastadisegni A, Pastore G. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J Hepatol 2000;32: 300-306
9. Tassopoulos NC, Volpes R, Pastore G, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/ hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology 1999;29:889-896
10. Food and Drug Administration Center of Drug Evaluation and Research. Approval Letter: Baraclude™ Available at: www.fda.gov/cder/foi/appletter/ 2005/021797,021798ltr.pdf. Last update: 2005. Accessed 2005
11. Hadziyannis SJ, Papatheodoridis GV. Emerging treatments in chronic hepatitis B. Expert Opin Emerg Drugs 2004;9:207-221
12. Colonno RJ, Genovesi EV, Medina I, et al. Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection. J Infect Dis 2001;184:1236-1245
13. de Man RA, Wolters LM, Nevens F, et al. Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. Hepatology 2001;34:578-582
14. Innaimo SF, Seifer M, Bisacchi GS, Standring DN, Zahler R, Colonno RJ. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother 1997;41:1444-1448
15. Lai CL, Rosmawati M, Lao J, et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 2002; 123:1831-1838
16. Seifer M, Hamatake RK, Colonno RJ, Standring DN. In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir. Antimicrob Agents Chemother 1998;42:3200-3208
17. Wolters LM, Hansen BE, Niesters HG, Dehertogh D, de Man RA. Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B. J Hepatol 2002;37:137-144
18. Chang TT, Gish R, de Man R, et al. Entecavir is superior to lamivudine for the treatment of HBeAg (+) chronic hepatitis B: results of phase III study ETV-022 in nucleoside-naive patients. Hepatology 2004;40(suppl 1):193A
19. Shouval D, Lai C-L, Cheinquer H, et al. Entecavir demonstrates superior histologic and virologic efficacy over lamivudine in nucleoside-naive HBeAg (-) chronic hepatitis B: results of phase III trial ETV-027. Hepatology 2004; 40(suppl 1):728A
20. Sollano J, Schiff E, Carrilho F, et al. Entecavir is well-tolerated for treatment of chronic hepatitis-B: phase III safety analysis in nucleoside-naive and lamivudine-refractory patients. Hepatology 2004;40:665A
21. Package Insert BaracludeAvailable at: www.fda.gov/cder/foi/ label/2005/021797,021798lbl.pdf. Last update: 2005. Accessed April 4, 2005
22. Sherman M, Yurdaydin C, Sollano J, et al. Entecavir is superior to continued lamivudine for the treatment of lamivudine-refractory, HBeAg (+) chronic hepatitis B: results of phase III study ETV-026. Hepatology 2004;40(suppl 1):664A
23. Rosmawati M, Schiff E, Parana R, et al. Entecavir is superior to lamivudine at reducing HBV DVA in patients with chronic hepatitis B regardless of baseline alanine aminotransferase levels. Hepatology 2004;40(suppl 1):656A
24. Colonno RJ, Rose RE, Levine SM, et al. Entecavir (ETV) resistance is not observed in nucleoside-naive subjects and is observed infrequently by week 48 in lamivudine-refractory subjects with chronic HBV infection. J Hepatol 2005; In press
25. Tenney DJ, Langley DR, Oliver AJ, et al. Hepatitis B virus resistance to entecavir involves novel changes in the viral polymerase. Hepatology 2004;40:245A
26. Warner N, Locarnini SA, Colledge D, et al. Molecular modelling of entecavir resistant mutations in the hepatitis B virus polymerase selected during therapy. Hepatology 2004;40(suppl 1):245A (abst 183)
27. Colonno RJ, Rose R, Levine SM, et al. Emergence of entecavir resistant hepatitis B virus after one year of therapy in phase II & III studies is only observed in lamivudine refractory patients. Hepatology 2004;40(suppl 1):661A
28. Chang TT, Hadziyannis S, Cianciara J, et al. Sustained viral load and ALT reduction following 48 weeks of entecavir treatment in subjects with chronic hepatitis B who have failed lamivudine. Hepatology 2002;36:300A
29. Honkoop P, de Man RA. Entecavir: a potent new antiviral drug for hepatitis B. Expert Opin Investig Drugs 2003;12: 683-688
30. Chen CJ, Yang HI, Su J, et al. Elevated serum level of hepatitis B virus DNA is an independent risk factor for hepatocellular carcinoma: a long-term follow-up study in Taiwan. J Hepatol 2005;45(suppl 1):abst 35A
31. Chen G, Lin W, Shen FM, et al. Viral load as a predictor of liver disease in chronic hepatitis B infection. Hepatology 2004;40:594A
32. Yang HI, Lu SN, Liaw YF, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002; 347:168-174
33. Bonino F, Rosina F, Rizzetto M, et al. Chronic hepatitis in HBsAg carriers with serum HBV-DNA and anti-HBe. Gastroenterology 1986;90(suppl 5 pt 1):1268-1273
34. Di Bisceglie AM. Long-term outcome of interferon-alpha therapy for chronic hepatitis B. J Hepatol 1995;22:65-67
35. Eddleston A. Interferons in the treatment of chronic hepatitis B virus infection. Med Clin North Am 1986;(suppl):25-30
36. Korenman J, Baker B, Waggoner J, Evert JE, Di Bisceglie AM, Hoofnagle JH. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med 1991;114: 629-634
37. Perry CM, Jarvis B. Peginterferon-alpha-2a (40 kD): a review of its use in the management of chronic hepatitis C. Drugs 2001;61:2263-2288
38. Glue P, Fang JW, Rouzier-Panis R, et al, for the Hepatitis C Intervention Therapy Group. Pegylated interferon-alpha 2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin Pharmacol Ther 2000;68:556-567
39. Cooksley WG, Piratvisuth T, Lee SD, et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 2003; 10:298-305
40. Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001;34:395-403
41. Reddy KR, Wright TL, Pockros PJ, et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001;33:433-438
42. Chan HL, Leung NW, Hui AY, et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med 2005;142:240-250
43. Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005;365:123-129
44. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352:2682-2695
45. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004;351:1206-1217
46. Bonino F, Lau G, Marcellin P, Hadzyannis S. The first detailed analysis of predictors of response in HBeAg-negative chronic hepatitis B: data from a multicenter, randomized, partially double-blind study of peginterferon alfa-2A (40KD) PEGASYS®) alone or in combination with lamivudine vs lamivudine alone. Hepatology 2005;40(suppl 1):659A
47. Lampertico P, Del Ninno E, Vigano M, et al. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology 2003;37:756-763
48. Manesis EK, Hadziyannis SJ. Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology 2001;121:101-109
49. Wursthorn K, Buggisch P, Zoellner B, et al. Combination therapy of peginterferon alfa-2b and adefovir dipivoxil in chronic hepatitis B leads to a strong suppresison of cccDNA and high rates of HBe and HBs seroconversion. J Hepatol 2005;45(suppl 1):abst 76
50. Hodge RA. Telbivudine/Torcitabine Idenix/Novartis. Curr Opin Investig Drugs 2004;5:232-241
51. Han SH, Leung NWY, Teo EK, et al. Results of a one-year international phase IIB trial of LDT, and LDT plus lamivudine, in patients with chronic hepatitis B. J Hepatol 2004;40:16
52. Lai CL, Lim SG, Brown NA, et al. A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection. Hepatology 2004;40:719-726
53. Lai CL, Brown NA, Myers M, et al. Valtorcitabine provides potent suppression of hepatitis B virus in patients with chronic hepatitis B: results of a phase I/II clinical trial (abst 24). Presented at: the 55th Annual Meeting of the American Association for the Study of Liver Disease; October 29-November 2, 2004. Boston, MA
54. Buti M, Esteban R. Entecavir, FTC, L-FMAU, LdT and others. J Hepatol 2003;39(suppl 1):S139-S142
55. Gish RG, Trinh H, Leung N, et al. Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: a two-year study. J Hepatol 2005;43:60-66
56. Gish RG, Leung NW, Wright TL, et al. Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection. Antimicrob Agents Chemother 2002;46:1734-1740
57. Gish R, Leung N, Wang C, et al. Antiviral activity, safety, and incidence of resistance in chronically infected hepatitis B patients (CHB) given once daily emtricitabine for 2 years. Hepatology 2003;38:372A
58. Shiffman ML, Ng TM, Krastev Z, et al. A double-blind, placebo-controlled trial of emtricitabine (ftc, Emtriva) administered once-daily for treatment of chronic hepatitis B virus (HBV) infection (abst 22). Presented at: the 55th Annual Meeting of the American Association for the Study of Liver Disease; October 29-November 2, 2004; Boston, MA
59. Cossart YE. Australia antigen and hepatitis in renal units. Proc Eur Dial Transplant Assoc 1972;9:235-242
60. Davis HL. DNA vaccines for prophylactic or therapeutic immunization against hepatitis B virus. Mt Sinai J Med 1999;66:84-90